Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe
Por:
Noguera-Julian A, Buonsenso D, Mckenna L, Seddon JA and Ritz N
Publicada:
1 sep 2021
Ahead of Print:
1 oct 2021
Categoría:
Medicine (miscellaneous)
Resumen:
Filiaciones:
Noguera-Julian A:
Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain
Center for Biomedical Network Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Déu Hospital Research Foundation, Barcelona, Spain
Both authors share credit for 1st authorship
Department of Pediatrics, University of Barcelona, Barcelona, Spain
Buonsenso D:
Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Ital
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Rome, Italy
Both authors share credit for 1st authorship
Mckenna L:
Treatment Action Group, New York, USA
Seddon JA:
Department of Infectious Diseases, Imperial College, London, UK
Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa
Ritz N:
Infectious Diseases Unit and Migrant Health Service, University Children's Hospital Basel, University of Basel, Basel, Switzerland
Department of Biomedicine, University of Basel, Basel, Switzerland
Department of Paediatrics, The University of Melbourne, Parkville, Australia
Bronze
|